Neurolief Secures $6M Investment to Expand Brain Neuromodulation Therapy Post FDA Approval Neurolief announces a $6 million investment to broaden access to its Proliv™Rx brain neuromodulation therapy, post FDA approval, for depression patients.

Neurolief Secures $6M Investment to Expand Brain Neuromodulation Therapy Post FDA Approval #USA #Coral_Springs #Neurolief #BrainsWay #ProlivRx

Neurolief's Proliv™Rx Receives FDA PMA for At-Home Depression Therapy Neurolief's Proliv™Rx is now FDA-approved as the first at-home brain neuromodulation therapy for adults with treatment-resistant depression, marking a significant advancement in mental health therapeutics.

Neurolief's Proliv™Rx Receives FDA PMA for At-Home Depression Therapy #USA #Depression #Coral_Springs #Neurolief #Proliv™Rx

Neurolief's MOOD Study Launches New Hope for Major Depressive Disorder Treatment Neurolief's recently published MOOD study paves the way for innovative neuromodulation therapy targeting Major Depressive Disorder, showing promising results.

Neurolief's MOOD Study Launches New Hope for Major Depressive Disorder Treatment #USA #Depression #Coral_Springs #Neurolief #ProlivRx

Neurolief and BrainsWay Unite to Launch Innovative Proliv™Rx for Depression Treatment Neurolief is set to transform depression treatment with its new at-home therapy, Proliv™Rx, thanks to strategic backing from BrainsWay.

Neurolief and BrainsWay Unite to Launch Innovative Proliv™Rx for Depression Treatment #USA #Coral_Springs #Neurolief #Proliv™Rx #BrainsWay

Neurolief Welcomes Dr. Owen Muir as Chief Medical Officer to Enhance Depression Treatment Solutions Neurolief has appointed Dr. Owen Muir as Chief Medical Officer to lead the charge in innovative treatments for depression, particularly with the launch of Proliv™Rx.

Neurolief Welcomes Dr. Owen Muir as Chief Medical Officer to Enhance Depression Treatment Solutions #USA #Tampa #Neurolief #Proliv™ #Dr._Muir